- Home
- FWRG vs PRTA Comparison
FWRG vs PRTA Comparison
Compare FWRG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWRG
- PRTA
- Stock Information
- Founded
- FWRG 1983
- PRTA 2012
- Country
- FWRG United States
- PRTA Ireland
- Employees
- FWRG N/A
- PRTA N/A
- Industry
- FWRG Restaurants
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- FWRG Consumer Discretionary
- PRTA Health Care
- Exchange
- FWRG Nasdaq
- PRTA Nasdaq
- Market Cap
- FWRG 970.4M
- PRTA 809.8M
- IPO Year
- FWRG 2021
- PRTA N/A
- Fundamental
- Price
- FWRG $15.83
- PRTA $5.72
- Analyst Decision
- FWRG Strong Buy
- PRTA Buy
- Analyst Count
- FWRG 11
- PRTA 9
- Target Price
- FWRG $21.82
- PRTA $27.67
- AVG Volume (30 Days)
- FWRG 867.5K
- PRTA 2.5M
- Earning Date
- FWRG 08-05-2025
- PRTA 08-07-2025
- Dividend Yield
- FWRG N/A
- PRTA N/A
- EPS Growth
- FWRG N/A
- PRTA N/A
- EPS
- FWRG 0.17
- PRTA N/A
- Revenue
- FWRG $1,055,701,000.00
- PRTA $137,935,000.00
- Revenue This Year
- FWRG $21.27
- PRTA N/A
- Revenue Next Year
- FWRG $16.07
- PRTA $119.20
- P/E Ratio
- FWRG $89.49
- PRTA N/A
- Revenue Growth
- FWRG 14.43
- PRTA 54.55
- 52 Week Low
- FWRG $12.90
- PRTA $4.32
- 52 Week High
- FWRG $22.71
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- FWRG 49.04
- PRTA 44.43
- Support Level
- FWRG $15.07
- PRTA $4.95
- Resistance Level
- FWRG $15.96
- PRTA $5.53
- Average True Range (ATR)
- FWRG 0.64
- PRTA 0.34
- MACD
- FWRG 0.09
- PRTA 0.24
- Stochastic Oscillator
- FWRG 76.88
- PRTA 78.29
About FWRG First Watch Restaurant Group Inc.
First Watch Restaurant Group Inc is a daytime restaurant concept serving made-to-order breakfast, brunch, and lunch using fresh ingredients. It generates revenues from Restaurant sales and Franchise revenues.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).